First line Immunotherapy for Non-Small Cell Lung Cancer

Nicola J. Nasser 1,*, Miguel Gorenberg 2 and Abed Agbarya 3

1 Department of Radiation Oncology, University of Maryland School of Medicine, Maryland Proton Treatment Center, Baltimore, MD 21201, USA
2 Department of Nuclear Medicine, Bnai Zion Medical Center; the Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31048, Israel; miguel.gorenberg@b-zion.org.il
3 Institute of Oncology, Bnai Zion Medical Center, Haifa 31048, Israel; abed.agbarya@b-zion.org.il
* Correspondence: nicola.nasser@gmail.com or nnasser@som.umaryland.edu

Received: 13 September 2020; Accepted: 5 November 2020; Published: 8 November 2020

Abstract: Immunotherapy for non-small cell lung cancer (NSCLC) is incorporated increasingly in first line treatments protocols. Multiple phase 3 studies have tested different medications targeting programmed death receptor 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), with or without chemotherapy. The inclusion criteria differ between the various clinical trials, including the cut-off levels of PD-L1 expression on tumor cells, and the tumor histology (squamous or non-squamous). Patients with tumor expression levels of PD-L1 ≥ 50% are candidates for treatment with single agent Pembrolizumab or Atezolizumab. Patients with PD-L1 < 50% are candidates for immunotherapy with pembrolizumab as a single agent if PL-1 > 1%; immunotherapy doublet, Nivolumab and Ipilimumab, or single agent immunotherapy combined with chemotherapy. Here we review phase 3 clinical trials utilizing immunotherapy in the first line for treatment of NSCLC, including Pembrolizumab in KEYNOTE-024, KEYNOTE-042, KEYNOTE-189 and KEYNOTE-407; Nivolumab and Ipilimumab in CHECKMATE-227 and CHECKMATE 9LA; and Atezolizumab in IMpower110, IMpower130 and IMpower150.

Keywords: lung cancer; monoclonal recombinant antibodies; chemotherapy; immune checkpoints inhibitors; programmed death receptor; CTLA-4

1. Introduction

Lung cancer is the leading cancer killer in both men and women in the Unites States, with over 135,000 deaths expected during 2020 [1]. Small cell lung cancer accounts for 15%, and non-small cell lung cancer (NSCLC) for 85% of lung cancer cases [2]. Immunotherapy for NSCLC uses monoclonal antibodies that targets immune system T cells or ligands on the tumors cells, and results in enhanced immune system mediated tumor-cell-kill [3].

T-cells primed to respond to tumor cell, are exposed continuously to tumor antigens during active malignancy, which may result in upregulation of multiple inhibitory receptors, culminating in less action against the tumor cell, in what is known as T-cell exhaustion [4]. T-cell exhaustion could be overcome by modulating the inhibitory pathways that are upregulated during this process [4]. Programmed death receptor 1 (PD-1) is expressed on the surface of T cells, and functions as an immune checkpoint that suppresses autoimmunity through multiple mechanisms [5], and is actually a marker of T-cell exhaustion. NSCLC tumor cells expressing programmed death-ligand 1 (PD-L1) could attach to PD-1 receptor on T cells, and result in decreased tumor cell kill by the immune system [6]. Pembrolizumab [7] and Nivolumab [8] are monoclonal antibodies that target PD-1 on T cells, and shield it from activation by tumors expressing PD-L1 (Figure 1), and thus results in enhanced immune activity.
Atezolizumab is a monoclonal antibody that targets PD-L1 on tumor cells, prevent it from activating PD-1 on T cells, which results in less suppression of T cell function [9] (Figure 1).

**Figure 1.** Non-small cell lung cancer (NSCLC) cells expressing programmed death-ligand 1 (PD-L1) could interact with programmed death receptor 1 (PD-1) expressed on the surface of T cells, and result in decreased tumor cell kill by the immune system. Atezolizumab is an anti PD-L1 monoclonal antibody. Nivolumab and Pembrolizumab are anti PD-1 monoclonal antibodies. Ipilimumab is a monoclonal antibody that targets Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of T cells. Bevacizumab is a monoclonal antibody that targets Vascular Endothelial Growth Factor (VEGF) in the circulation and functions as an angiogenesis inhibitor.

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a receptor on T cells that functions as an immune checkpoint that downregulates immune responses [10]. Ipilimumab is a monoclonal antibody that targets CTLA-4 and inhibits its activation and thus stimulates the immune system [11] (Figure 1). Dual blockade CTLA-4 and PD-1 therapy was shown to have enhanced efficacy of tumor cell kill in multiple preclinical and clinical trials [12,13], though with an increase in immune related adverse events with these combinations.

Here we will focus mainly on the role of immunotherapy in the first line treatment of NSCLC. This review will not get into details regarding the treatment of patients with driver mutations, such as anaplastic lymphoma kinase (ALK)-EML4 gene translocation [14] or mutations in the epidermal growth factor receptor (EGFR) [15] as they were excluded from most phase 3 clinical trials incorporating immunotherapy in the first line [16–19].

2. Monoclonal Antibodies Targeting Immune Checkpoints

Immune checkpoints refer to inhibitory pathways incorporated in the immune system that are crucial for maintaining self-tolerance [20], and are negative regulators of T-cell immune function. Antibodies targeting immune checkpoints results in enhanced immune mediated tumor cell kill (Table 1).
Table 1. Antibodies targeting the immune system used for treatment of lung cancer.

| Generic Name   | Brand Name  | Antibody Type                     | Indications and Usage Other than NSCLC                                                                 | Target | Half-Life (Days) |
|----------------|-------------|-----------------------------------|---------------------------------------------------------------------------------------------------------|--------|------------------|
| Pembrolizumab  | Keytruda    | Humanized IgG4 kappa              | • Melanoma • Small Cell Lung Cancer • Head and Neck Squamous Cell Cancer • Classical Hodgkin Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • Urothelial Carcinoma • MSI-H or dMMR Cancers • Gastric Cancer • Esophageal Cancer • Cervical Cancer • Hepatocellular Carcinoma • Merkel Cell Carcinoma • Renal Cell Carcinoma • Endometrial Carcinoma • Tumor Mutational Burden-High Cancer • Cutaneous Squamous Cell Carcinoma | PD-1   | 22               |
| Nivolumab      | Opdivo      | Fully human IgG4 kappa            | • Melanoma • Small Cell Lung Cancer • Head and Neck Squamous Cell Cancer • Classical Hodgkin Lymphoma • Urothelial Carcinoma • MSI-H or dMMR colorectal cancer • Hepatocellular Carcinoma • Renal Cell Carcinoma • Esophageal Squamous Cell Carcinoma | PD-1   | 25               |
| Atezolizumab   | Tecentriq   | Humanized non-glycosylated IgG1 kappa | • Urothelial Carcinoma • Triple-Negative Breast Cancer • Small Cell Lung Cancer • Hepatocellular Carcinoma • Melanoma | PD-L1  | 27               |
| Ipilimumab     | Yervoy      | Fully human IgG1 kappa            | • Melanoma • Renal Cell Carcinoma • MSI-H or dMMR colorectal cancer • Hepatocellular Carcinoma | CTLA-4 | 15               |
| Durvalumab     | Imfinzi     | Fully human IgG1 kappa            | • Urothelial Carcinoma • Small Cell Lung Cancer | PD-L1  | 18               |

PD-1: programmed death receptor-1; PD-L1: programmed cell death ligand 1; CTLA-4: cytotoxic T-lymphocyte antigen 4; MSI-H: Microsatellite Instability-High; dMMR: Mismatch Repair Deficient.
2.1. Nivolumab

Nivolumab is a fully human IgG4 antibody targeting PD-1. Nivolumab is provided intravenously, with a mean half-life of 25 days [21]. No dose adjustment is recommended in patients with renal failure, and mild or moderate hepatic impairment [21]. Most common adverse reactions in patients treated with Nivolumab as a single agent are fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper respiratory tract infection, pyrexia, headache, abdominal pain, and vomiting [21,22]. Immune-mediated side effects were reported and includes pneumonitis, thyroiditis which could manifest as hypothyroidism and hyperthyroidism [23–26], colitis [27], hepatitis [28], and nephritis [29].

2.2. Pembrolizumab

Pembrolizumab is a humanized IgG4 antibody targeting PD-1. Pembrolizumab is provided intravenously, with a mean half-life of 22 days [30]. No dose adjustment is recommended in patients with renal failure, or mild hepatic impairment [30]. Most common adverse reactions in patients treated with Pembrolizumab as a single agent are fatigue, musculoskeletal pain, decreased appetite, pruritus, diarrhea, nausea, rash, pyrexia, cough, dyspnea, constipation, and abdominal pain [30–33]. Immune-mediated side effects were reported and includes pneumonitis [34], colitis [35,36], hepatitis [37,38], adrenal insufficiency [39,40], hypophysitis [39], hyperthyroidism [41] and hypothyroidism [42,43], type 1 diabetes mellitus [44,45], and nephritis [46,47].

2.3. Atezolizumab

Atezolizumab is a humanized IgG1 antibody targeting PD-L1. Atezolizumab is provided intravenously, with a half-life of 27 days. Mild or moderate renal failure (estimated glomerular filtration rate (eGFR) \( \geq 30 \text{ mL/min/1.73 m}^2 \)) and mild to moderate liver failure (bilirubin < 3 \times upper limit of normal and any aspartate transaminase levels) had no clinically significant effect on the systemic exposure of atezolizumab [48]. The most common adverse reactions in patients treated with Atezolizumab as a single agent are fatigue, nausea, cough, dyspnea, and decreased appetite [48]. Immune-mediated side effects were reported and includes pneumonitis [49–51], hepatitis [52,53], colitis [53], hypophysitis [54], thyroid disorders [55], adrenal insufficiency [56], and type 1 diabetes mellitus [57].

2.4. Ipilimumab

Ipilimumab is a fully human IgG1 kappa antibody targeting CTLA-4. Ipilimumab is provided intravenously, with a half-life of 15.4 days [58]. The following factors had no clinically important effect on the clearance of ipilimumab: Age, sex, performance status, renal impairment (glomerular filtration rate (eGFR) \( \geq 15 \text{ mL/min/1.73 m}^2 \)), or mild hepatic impairment (total bilirubin > 1 to 1.5 times the upper limit of normal or any aspartate transaminase levels) had no clinically significant effect on the systemic exposure of ipilimumab [58]. The most common adverse reactions with Ipilimumab as a single agent are fatigue, diarrhea, pruritus, rash, colitis, nausea, vomiting, headache, weight loss, pyrexia, decreased appetite, and insomnia [58]. Immune-mediated adverse reactions to Ipilimumab were reported and includes pneumonitis [59], colitis [60,61], nephritis [62–65], myocarditis [57]; endocrinopathies, including thyroid disorders [66], adrenal insufficiency [67], type 1 diabetes mellitus [68,69], and hypophysitis/hypopituitarism [58].

2.5. Durvalumab

Durvalumab is a fully human IgG1 kappa antibody targeting PD-L1. Durvalumab is provided intravenously, with a half-life of 18 days [70]. Mild (creatinine clearance 60 to 89 mL/min) or moderate renal impairment (creatinine clearance 30 to 59 mL/min), and mild hepatic impairment (bilirubin \( \leq \) upper limit of normal and aspartate transaminase levels > upper limit of normal or bilirubin > 1 to 1.5 \times upper limit of normal and any aspartate transaminase levels) had no clinically significant effect on the pharmacokinetics of durvalumab [70]. The most common adverse reactions with
Durvalumab as a single agent are fatigue, constipation, rash, nausea, dyspnea, swelling in the arms and legs, and decreased appetite. Immune-mediated adverse reactions to Durvalumab which were reported include pneumonitis [71,72], hepatitis [71,73], colitis [74], nephritis [74], dermatologic reactions [75,76], and endocrinopathies, including thyroiditis [77,78], adrenal insufficiency [77], and type 1 diabetes mellitus [77–79].

3. Chemotherapeutic Agents Used for Treatment of NSCLC Together with Immunotherapy

3.1. Platinum Based Chemotherapeutic Agents

Chemotherapy for NSCLC usually includes combination of two drugs (chemotherapy doublet), with one of the agents is cisplatin or carboplatin. In 2002, Schiller at al. published in the New England Journal of Medicine, a study that compared four chemotherapy regimens for advanced NSCLC, cisplatin and paclitaxel, cisplatin and gemcitabine, cisplatin and docetaxel, and carboplatin and paclitaxel [80]. The study was well powered, with 1207 patients enrolled. None of the four chemotherapy regimens offered a significant advantage over the others [80]. In 2008, Scagliotti et al. [81] published in the Journal of Clinical Oncology a study that compared cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced NSCLC [81]. Overall survival was statistically superior for cisplatin/pemetrexed versus cisplatin/gemcitabine in patients with adenocarcinoma and large-cell carcinoma histology, while patients with squamous cell histology had a significant improvement in survival with cisplatin/gemcitabine versus cisplatin/pemetrexed [81]. These two studies made significant impact on the chemotherapy choices for treating NSCLC, with cisplatin or carboplatin as the backbone of all the chemotherapy treatments protocols. Pemetrexed is provided with platinum-based chemotherapy to patients with nonsquamous NSCLC. Gemcitabine is provided with platinum-based drug to patients with squamous NSCLC.

3.1.1. Cisplatin

Cisplatin is composed of a central atom of platinum with two chloride atoms and two ammonia molecules attached to it in the cis position. Cisplatin is provided intravenously and exerts its cytotoxic effects through binding to the deoxyribonucleic acid (DNA) strands, making inter- and intra- strands cross-links, which results in disruption of transcription and translation of DNA. Nephrotoxicity is the dose limiting toxicity of cisplatin, which results mainly from proximal tubular injury [82]. Other side effects of cisplatin include nausea and vomiting which usually necessitate premedication with antiemetic medications before cisplatin infusion, ototoxicity which could manifest in varying levels of hearing loss, peripheral neuropathy, and myelosuppression.

3.1.2. Carboplatin

Carboplatin, like cisplatin is composed of a central atom of platinum and two ammonia molecules, but the two chloride atoms are substituted by a cyclobutenedicarboxylate moiety. Carboplatin is provided intravenously and exerts its cytotoxic effects through inter- and intra- DNA strands cross-links, which results in disruption of transcription and translation of DNA. Bone marrow suppression is the dose-limiting toxicity of carboplatin. Carboplatin is much less nephrotoxic compared to cisplatin and is used as an alternative to cisplatin for patients with preexisting renal failure.

3.2. Taxanes

Taxanes are microtubule-stabilizing drugs which induces mitotic arrest at the G2/M transition phase of the cell cycle, resulting in cell death. Paclitaxel was isolated from bark extract of the Pacific yew tree. Docetaxel is a semisynthetic taxane and nab-paclitaxel is a nanoparticle albumin-bound paclitaxel.
3.2.1. Paclitaxel

Paclitaxel binds to tubulin and stabilizes the microtubules which leads to inhibition of cell division. Paclitaxel is provided intravenously, with a dose limiting toxicity of peripheral neuropathy. Peripheral sensory neuropathy presents with numbness and tingling in a stocking-and-glove distribution [83], which may disturb daily function of the patients. Hematologic toxicity include anemia, neutropenia, and less frequently thrombocytopenia.

3.2.2. Docetaxel

Docetaxel is provided intravenously, and acts in similar manner to paclitaxel. Docetaxel binds to tubulin, the protein component of the microtubules, and inhibits its disassembly, which results in disruption of mitosis and cell death. Docetaxel appears twice as active as paclitaxel in microtubules depolymerization inhibition [84]. Some clinical studies show that Docetaxel seems to be more potent compared with Paclitaxel, especially for treatment of breast cancer patients [85,86]. Hematological toxicities are the dose limiting toxicity of Docetaxel with neutropenia and anemia. Other side effects include alopecia, stomatitis, diarrhea, nausea, vomiting, fluid retention, onycholysis, and skin toxicity [87,88].

3.2.3. Nanoparticle Albumin-Bound Paclitaxel

Nanoparticle albumin-bound (nab) paclitaxel is an Albumin bound with high affinity to the hydrophobic molecules of paclitaxel, which results in higher accumulation of the cytotoxic drug in tumors. A recent meta-analysis showed that when compared to Paclitaxel, nab-paclitaxel has significant beneficial effects in terms of overall response rate, progression free survival, and overall survival [89]. Side effects of nab-paclitaxel include anemia, neutropenia, alopecia, and peripheral neuropathy [90].

3.3. Gemcitabine

Gemcitabine is structurally similar to cytarabine and functions as a pyrimidine analog, and blocks the progression of cells through the G1/S-phase [91]. Gemcitabine is metabolized by nucleoside kinases to Gemcitabine diphosphate and Gemcitabine triphosphate. Gemcitabine diphosphate inhibits ribonucleotide reductase, resulting in reductions in deoxynucleotide concentrations, including deoxyctydine triphosphate. Gemcitabine triphosphate competes with deoxyctydine triphosphate for incorporation into DNA [91]. Side effects of Gemcitabine includes myelosuppression manifested by neutropenia, thrombocytopenia, and anemia [91,92]; pulmonary toxicity, including interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, and adult respiratory distress syndrome [91,93,94]; capillary leak syndrome [95–97]; and posterior reversible encephalopathy syndrome [98,99].

3.4. Pemetrexed

Pemetrexed functions as an antimetabolite. Pemetrexed inhibits thymidylate synthase, dihydrofolate reductase and glycaminide ribonucleotide formyltransferase. Pemetrexed induces cell cycle arrest in the G1/S phase. Side effects of Pemetrexed includes myelosuppression [100], renal failure [100], bullous and exfoliative skin toxicity [100–102], diarrhea, nausea, and vomiting [100].

4. Phase 3 Randomized Controlled Trials that Includes Immunotherapy for NSCLC

Phase 3 randomized controlled trials that compare immunotherapy as a single modality or in combination with other systemic therapies, to the standard of care that was before the publication of these trials are described in Figures 2 and 3. These trials included Pembrolizumab in KEYNOTE-024, KEYNOTE-042, KEYNOTE-189 and KEYNOTE-407; Nivolumab and Ipilimumab in CHECKMATE-227 and CHECKMATE 9LA; and Atezolizumab in IMpower110, IMpower130 and IMpower150. The monoclonal antibodies used in each of these trials and/or the cytotoxic
chemotherapeutic agents in each arm, the overall survival, and the hazard ratios for benefit are detailed in Table 2.

**Figure 2.** The main treatment arms of phase 3 clinical trials providing immunotherapy in the first line for patients with non-small cell lung cancer.

**Figure 3.** Comparison of over survival and hazard ratios (HR) in clinical trials incorporating immunotherapy in the first line for patients with non-small cell lung cancer. The treatment arms without and with immunotherapy are compared in KEYNOTE-024, KEYNOTE-042, KEYNOTE-189, KEYNOTE-407, CHECKMATE-227, CHECKMATE 9LA, IMpower110, IMpower130, and IMpower150.
Table 2. Phase 3 clinical trials that includes Immunotherapy for NSCLC in the first line.

| Table 2 | Pathology | PDL-1   | Arm I (OS)                  | Arm II (OS)                  | HR   |
|---------|-----------|---------|----------------------------|----------------------------|------|
| KEYNOTE-024 | squamous (18%) and nonsquamous (82%) | ≥50%  | Pembrolizumab             | Investigator’s choice of platinum-based chemotherapy | 0.63 |
|         |           |         | 30 months                 | 14.2 months                 |      |
| KEYNOTE-042 | squamous (38%) and nonsquamous (62%) | ≥1%   | Pembrolizumab             | Investigator’s choice of platinum-based chemotherapy doublet | 0.81 |
|         |           |         | 16.7 months               | 12.1 months                 |      |
| KEYNOTE-189 | nonsquamous | Any level | Pembrolizumab & Pemetrexed + Cisplatin/Carboplatin | Pemetrexed + Cisplatin/Carboplatin | 0.56 |
|         |           |         | 22 months                 | 10.7 months                 |      |
| KEYNOTE-407 | squamous | Any level | Pembrolizumab & Carboplatin + paclitaxel or nab–paclitaxel | Carboplatin + paclitaxel or nab–paclitaxel | 0.64 |
|         |           |         | 15.9 months               | 11.3 months                 |      |
| CHECKMATE-227 | squamous (28%) and nonsquamous (72%) | ≥1% <1% | Nivolumab and Ipilimumab | Cisplatin/Carboplatin + Gemcitabine (for squamous) or pemetrexed (nonsquamous) | 0.79 |
|         |           |         | 17.1 months               | 14.9 months                 |      |
|         |           |         | 17.2 months               | 12.2 months                 |      |
| CHECKMATE 9LA | squamous and nonsquamous | Any level | Nivolumab & Ipilimumab + Cisplatin/Carboplatin + Pemetrexed/Paclitaxel | Cisplatin/Carboplatin + Pemetrexed/Paclitaxel | 0.66 |
|         |           |         | 15.6 months               | 10.9 months                 |      |
| IMpower110 | squamous (25%) and nonsquamous (75%) | ≥50%  | Atezolizumab             | Gemcitabine (for squamous) or pemetrexed (nonsquamous) | 0.59 |
|         |           |         | 20.2 months               | 13.1 months                 |      |
| IMpower130 | non-squamous | Any level | Atezolizumab & Carboplatin + nab–paclitaxel | Carboplatin + nab–paclitaxel | 0.79 |
|         |           |         | 18.6 months               | 13.9 months                 |      |
| IMpower150 | non-squamous | Any level | Atezolizumab + Bevacizumab + Carboplatin, and Paclitaxel | Bevacizumab + Carboplatin, and Paclitaxel | 0.76 |
|         |           |         | 19.8 months               | 14.9 months                 |      |
4.1. Keynote-024

Keynote-024 [32,33] is a phase 3 trial that compared Pembrolizumab versus platinum-based chemotherapy-doublet for PD-L1 positive NSCLC. The chemotherapy used was the investigator’s choice of platinum-based chemotherapy doublet. The trial included patients with squamous (18%) and nonsquamous (82%) histology with PD-L1 expression on at least 50% of tumor cells. Most patients were current or former smokers (92%). Median overall survival (OS) was 30.0 months with pembrolizumab and 14.2 months with chemotherapy, hazard ratio 0.63, \( p = 0.002 \) [32]. Pembrolizumab was associated with significantly fewer adverse events than was platinum-based chemotherapy [33]. Survival curves started to split early, about 1.5 months after the trial initiation, probably due to more efficacy and less toxicity of pembrolizumab compared to chemotherapy.

1. Median OS in this study is 30 months, to our knowledge the longest among first line studies of NSCLC.
2. Interestingly, females benefited much less than males with pembrolizumab compared to chemotherapy. HR for benefit among men was 0.54, and among women was 0.95. Absolute survival numbers among sexes were not published in the original [33] or updated analysis [32]. This was not a preplanned analysis, and interpretation of the results regarding the patients’ sex should be taken with caution.
3. Never smokers had less benefit from Pembrolizumab versus chemotherapy (HR 0.9) compared to smokers (HR 0.59).

4.2. Keynote-042

KEYNOTE-042 [31] included NSCLC with locally advanced or metastatic disease without previous treatment and without a driving mutation in EGFR or ALK translocation, and with PD-L1 tumor proportion score (TPS) of 1% or greater. Similar to Keynote-024 [32], the trial included patients with squamous and nonsquamous histology, most of them current or former smokers [31]. This phase 3 trial compared Pembrolizumab versus the investigator’s choice of platinum-based chemotherapy doublet. Median OS was 16.7 months with Pembrolizumab and 12.1 months with chemotherapy, hazard ratio 0.81, \( p = 0.0018 \). For patients with PD-L1 TPS of 50% or greater, median OS was 20 and 12.2 months in the Pembrolizumab and chemotherapy groups, respectively. Interestingly, compared to Keynote-024 the survival curves opened later, at about 8 months.

1. Compared to KEYNOTE-024, OS in KEYNOTE-042 was less even in patients with PD-L1 \( \geq \) 50%.
2. The similar OS in the initial months of the study between the chemotherapy and Pembrolizumab arms, trending initially to better results with chemotherapy before the curves crosses, indicates that combination therapy could provide better outcomes in a subset of patients.
3. Female patients had less benefit compared to male patients. HR for benefit among men was 0.71 and among women was 1.01. This is consistent with KEYNOTE-024 that showed no improved survival for women with Pembrolizumab compared to chemotherapy. This was not a preplanned analysis, and interpretation of the results regarding the patients’ sex should be taken with caution.
4. Never smokers did worse with Pembrolizumab versus chemotherapy, with HR of 1.1, compared to 0.6 and 0.71 in former and current smokers, as reported in the publication supplementary appendix [103].

4.3. Keynote-189 and Keynote-407

KEYNOTE-189 [104,105] and KEYNOTE-407 [103] compared chemotherapy to chemotherapy and pembrolizumab in patients with nonsquamous and squamous NSCLC, respectively, as first line therapy. There was survival benefit for pembrolizumab for patients groups with any PD-L1 expression levels [103,104].
4.3.1. Keynote-189

This study compared chemotherapy to chemotherapy and pembrolizumab in patients with nonsquamous NSCLC as first line therapy. The chemotherapy used was Pemetrexed + Cisplatin/Carboplatin. Among patients with nonsquamous NSCLC with any PD-L1 expression level, OS was 22 versus 10.7 months with Pembrolizumab and chemotherapy compared to chemotherapy alone, HR 0.56 [104]. For patients with PD-L1 ≥ 50%, OS was 20.4 to not reached with Pembrolizumab and chemotherapy, compared to 10.1 months with chemotherapy alone [104]. We will be waiting for the updated analysis of this study to see if OS for combination therapy for patients with PD-L1 ≥ 50% will exceed those of Keynote-024 [32]. For patients with nonsquamous NSCLC and PD-L1 < 1% this trial shows clear benefit for adding Pembrolizumab to chemotherapy. Furthermore, patients with liver metastasis benefited from the combination, with OS of 12.6 versus 6.6 months in the Pembrolizumab and chemotherapy compared to chemotherapy alone groups, respectively [104]. The combination was effective in both female and male patients, and in smokers and non-smokers [105].

4.3.2. Keynote-407

Keynote-407 compared chemotherapy to chemotherapy and pembrolizumab in patients with squamous NSCLC as first line therapy [103]. The chemotherapy used was Carboplatin + paclitaxel or nab–paclitaxel. Among patients with squamous NSCLC with any PD-L1 expression level, OS was 15.9 versus 11.3 months with Pembrolizumab and chemotherapy compared to chemotherapy alone, respectively, HR 0.64. More than 92% of the patients were current or former smokers. Both males and females benefited from the combination [103]. Furthermore, here, OS did not reach those of Keynote-024 [32,33], and was similar to those of KEYNOTE-042 [31], which keep us with the question if there is an added benefit of chemotherapy compared to single agent Pembrolizumab in smoker male patients with PD-L1 ≥ 1%. A randomized trial in NSCLC patients, testing Pembrolizumab alone versus Pembrolizumab and chemotherapy will be needed to answer this question.

4.4. IMpower110

IMpower110 randomized patients with stage IV NSCLC with PD-L1 expression ≥ 1% to Atezolizumab single agent or to chemotherapy [106]. The chemotherapy used was Cisplatin or Carboplatin, combined with Gemcitabine for patient with squamous cell NSCLC, or pemetrexed for patients with nonsquamous disease. Atezolizumab was better tolerated than chemotherapy. In the subgroup of patients with EGFR and ALK wild-type tumors who had PD-L1 stained ≥ 50% of tumor cells (205 patients), the OS was 20.2 months with Atezolizumab, and 13.1 months with chemotherapy, according to the U.S. Food & Drug Administration approval and recent publication in the New England Journal of Medicine [107,108]. FDA approval is for patients with PD-L1 stained ≥ 50% of tumor cells, or PD-L1 stained tumor-infiltrating immune cells covering ≥ 10% of the tumor area, with no EGFR or ALK genomic tumor aberrations.

4.5. IMpower130

IMpower130 was an open-label, phase 3 trial that compared Atezolizumab in combination with carboplatin plus nab–paclitaxel chemotherapy, with chemotherapy alone as first-line treatment for metastatic non-squamous NSCLC [56]. About half of the patients had PD-L1 negative tumors. Median OS was 18.6 months in the atezolizumab plus chemotherapy group and 13.9 months in the chemotherapy group; HR 0.79, p = 0.033 [56]. Subgroup analysis showed progression free survival (PFS) benefit, and a trend toward OS benefit in all PD-L1 expression levels.

4.6. IMpower150

IMpower150 randomized patients with nonsquamous NSCLC to treatment with chemotherapy plus Bevacizumab, chemotherapy plus atezolizumab or chemotherapy plus Bevacizumab and
atezolizumab [55,109,110]. The chemotherapy used was Carboplatin, and Paclitaxel. Median OS was 19.8 and 14.9 months for patients treated with chemotherapy plus Bevacizumab, with or without atezolizumab, respectively [55,109], (Figure 3). Median OS with Atezolizumab and chemotherapy alone was 19.5 months [109], raising question with regard to the added value of Bevacizumab to this combination for the general patients population. Importantly, patients with baseline liver metastases had an improved OS with Atezolizumab, Bevacizumab, and chemotherapy combination, compared to Bevacizumab and chemotherapy alone, with a median OS of 13.3 and 9.4 months, respectively, HR 0.52 [109]. No improvement in OS was observed for patients with liver metastasis treated with chemotherapy and atezolizumab compared to patients treated with chemotherapy and Bevacizumab [109]. Recent report about safety and patient-reported outcomes of atezolizumab plus chemotherapy and Bevacizumab shows that this drug combination seems tolerable and with manageable toxicities [110]. For patients with nonsquamous NSCLC, with baseline liver metastases, the combination of chemotherapy, Atezolizumab and Bevacizumab could be an important option to consider in the first line.

4.7. Checkmate-227

CHECKMATE-227 included patients with stage IV or recurrent NSCLC without previous treatment. Patients with a PD-L1 expression level of 1% or more were randomized in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The chemotherapy used was Cisplatin or Carboplatin, combined with Gemcitabine for patient with squamous cell NSCLC, or pemetrexed for patients with nonsquamous disease. The OS was 17.1, 15.7 and 14.9 months, respectively [111] (Figure 4). The patients who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy. The OS was 17.2, 15.2 and 12.2 months, respectively [111] (Figure 4).

![Figure 4. Overall survival results in CHECKMATE-227.](image)

Subgroup analysis published as an appendix to the main publication [111] shows multiple interesting points:
1. Patients who never smoked had OS of 15.3 months with nivolumab plus ipilimumab compared to 16.1 months with chemotherapy alone [111].

2. Patients with PD-L1 < 1% and liver metastasis had a statistically significant benefit from nivolumab plus ipilimumab compared to chemotherapy with survival of 11.7 versus 7.8 months, respectively. This significance was not maintained in patients with PD-L1 ≥ 1 and liver metastasis. For patients, regardless of PD-L1, with liver metastasis, survival was 10.3 months with nivolumab plus ipilimumab compared to 10.4 months with chemotherapy [111].

3. Nivolumab plus ipilimumab was beneficial compared to chemotherapy in patients above and below the age of 65 years.

4. Ipilimumab was provided at a dose of 1 mg per kilogram every 6 weeks [111], which is much lower than the dose used for melanoma [112].

4.8. Checkmate-9LA

CHECKMATE-9LA [113] randomized patients with stage IV NSCLC, to nivolumab 360 mg Q3W + ipilimumab 1 mg/kg Q6W + two cycles of chemotherapy or 4 cycles of chemotherapy alone. The chemotherapy used was Cisplatin or Carboplatin combined with Pemetrexed or Paclitaxel. The data were presented in an abstract format and as a lecture during the American Society of Clinical Oncology (ASCO) 2020 annual meeting [113]. Median OS was 15.6 and 10.9 months, in the immunotherapy-chemotherapy and the chemotherapy only groups, respectively. Subgroup analysis showed:

(1) Clinical benefit for the combination of immunotherapy-chemotherapy was seen over chemotherapy only, regardless of PD-L1 expression.

(2) Never smokers had worse survival outcome with the immunotherapy-chemotherapy combination compared to chemotherapy only, with a median OS of 14.1 versus 17.8 months, respectively.

(3) Patients ≥ 75-year-old did worse with the immunotherapy-chemotherapy compared to chemotherapy only, with median OS of 8.5 versus 11.5 months, respectively.

5. Discussion

The treatment of advanced/metastatic NSCLC has changed dramatically in the last 10 years. First line therapies that incorporates immunotherapy, either as a single modality or with chemotherapy, can be offered to significant part of NSCLC patients. These advances in lung cancer therapeutics, along with other causes, resulted in a decrease in population-level mortality from NSCLC in the United States from 2013 to 2016 [114]. Figure 5 provides an algorithm for treatment of patients with NSCLC.

5.1. PD-L1 ≥ 50%

Patients with PD-L1 ≥ 50% have multiple immunotherapy treatment options. Monotherapy is an appealing approach, with median OS of 30 months with pembrolizumab single agent compared to 14.2 months with chemotherapy, in KEYNOTE-024 [32]. OS for patients with PD-L1 ≥ 50% treated with pembrolizumab single agent in KEYNOTE-042 study was 20 months, compared to 12.2 months with chemotherapy [31]. Hazard ratio for OS benefit from pembrolizumab compared to chemotherapy for never-smokers was 0.9 and 1.1 in KEYNOTE024 and KEYNOTE042, respectively. This might indicate that never smokers do not have survival benefit with pembrolizumab compared to chemotherapy (subgroup analysis was not tested in a prospective manner). For females, HR was 0.95 and 0.78 in KEYNOTE024 and KEYNOTE042, respectively, indicating that female patients might benefit less from pembrolizumab compared to male patients, again subgroup analysis was not tested in a prospective manner. Thus for never smokers and for female patients with NSCLC we would suggest to consider adding chemotherapy to pembrolizumab as per Keynote 189 [104] and Keynote 407 [103]. In addition, finding molecular markers for aggressive, early progressing nononcogene-addicted NSCLC [115], could
allow testing treatment intensification in the first line, and the role of combing immunotherapy [116] and chemotherapy in this subset of patients.

Atezolizumab for first-line treatment of metastatic NSCLC with PD-L1 ≥ 50% was approved recently by the FDA [107], after the IMPOWER110 trial showed a median OS of 20.2 months for patients in the atezolizumab arm, compared with 13.1 months in the chemotherapy arm ($p = 0.0106$) [107,108].

### NSCLC Treatment Algorithm

| Subgroup | Treatment | Comments |
|----------|-----------|----------|
| ALK/EML4+ EGFR mutation ROS1+ BRAF V600E MET exon 14 skipping RET rearrangement+ | | Consider Targeted therapies |
| PD-L1 ≥ 50% | Pembrolizumab single agent (KEYNOTE024 / KEYNOTE042) | HR for OS for never-smokers 0.9 and 1.1, and for females 0.95 and 0.78 in KEYNOTE024 and 042, respectively *. Consider adding chemotherapy as per Keynote 189/407 for females / never smokers |
| Pembrolizumab + Chemotherapy (KEYNOTE189 / KEYNOTE407) | Never-smokers had nonsignificant worse survival outcome compared to chemotherapy * |
| Atezolizumab + Chemotherapy (IMpower130) | Nonsquamous only |
| Pembrolizumab single agent (KEYNOTE042) | non-smokers and females had nonsignificant benefit compared to chemotherapy * |
| Pembrolizumab + Chemotherapy (KEYNOTE189 / KEYNOTE407) | OS benefit for Smokers/Non-Smokers/Females / Males / Liver Metastases* |
| Atezolizumab + Chemotherapy (IMpower130) | Nonsquamous only |
| Bevacizumab + chemotherapy + atezolizumab (IMpower150) | Nonsquamous only Benefit also in patients with liver metastasis* |
| Nivolumab + Ipilimumab (CHECKMATE-227) | Patients with liver Mets and never-smokers did not benefit compared to chemotherapy * |
| Nivolumab + Ipilimumab+ Chemotherapy (CHECKMATE-9LA) | Never smokers and patients > 75 years had worse survival outcome * |
| Pembrolizumab + Chemotherapy (KEYNOTE189 / KEYNOTE407) | OS benefit for Smokers/Non-Smokers/Females / Males / Liver Metastases * |
| Atezolizumab + Chemotherapy (IMpower130) | Nonsquamous only |
| Bevacizumab + chemotherapy + atezolizumab (IMpower150) | Nonsquamous only Benefit also in patients with liver metastasis * |
| Nivolumab + Ipilimumab (CHECKMATE-227) | Patients with liver Mets benefited. Never-smokers did not benefit compared to chemotherapy * |
| Nivolumab + Ipilimumab+ Chemotherapy (CHECKMATE-9LA) | Never smokers and patients > 75 years had worse survival outcome * |

* This was not a preplanned primary endpoint, interpretation of the results should be taken with caution

**Figure 5.** Algorithm for treatment of patients with non-small cell lung cancer (NSCLC).
5.2. PD-L1 1–49%

Monotherapy with pembrolizumab as per KEYNOTE-042 is an appealing option, especially for smoker males [31]. Combination of Nivolumab and Ipilimumab as per Checkmate 227 [111] is an option, thought there is no head to head comparison with pembrolizumab, and toxicity with the doublet is expected to be higher than in monotherapy. Pembrolizumab and chemotherapy should be considered for nonsmokers, patients with aggressive disease, and patients with liver metastases [103,104]. Atezolizumab plus chemotherapy is also an option to consider [56]. Nivolumab, ipilimumab and chemotherapy could be considered for smoker patients younger than 75 years [113].

5.3. PD-L1 <1%

Immunotherapy only (chemotherapy free) protocols suitable for this subset of patients, is a combination of Nivolumab and Ipilimumab as per Checkmate 227 [111]. Immunotherapy with 2 courses only of chemotherapy is another option for smoker patients younger than 75 years, as per Checkmate-9LA [113]. Pembrolizumab and chemotherapy could be an excellent option for many patients with PD-L1 <1% [103,104], as well as Atezolizumab plus chemotherapy [56].

5.4. Negative Immunotherapy Studies

While immunotherapy is now the leading treatment for many patients with lung cancer, it is important to remember that there were multiple negative trials. Durvalumab is a monoclonal antibody that block PD-L1 [74,117]. Tremelimumab is a monoclonal antibody targeting CTLA-4 [118]. Durvalumab with tremelimumab showed a manageable tolerability profile, with antitumor activity irrespective of PD-L1 status, in patients with NSCLC in a phase 1b study [119]. The combination was tested after that in phase 3 studies. The MYSTIC Trial tested Durvalumab with or without tremelimumab vs. standard chemotherapy in the first-line treatment of metastatic NSCLC [120]. The trial did not meet its primary end points of improved OS with durvalumab versus chemotherapy, or improved OS or PFS with durvalumab plus tremelimumab versus chemotherapy in patients with ≥25% of tumor cells expressing PD-L1 [120]. First-Line Nivolumab in Stage IV or recurrent NSCLC was not associated with significantly longer PFS than chemotherapy [22].

5.5. Chemo-Free or Chemo-Light Treatments

Until the publication of the CHECKMATE-227 and CHECKMATE 9LA studies, first line therapy for NSCLC included single agent immunotherapy with or without chemotherapy. These studies showed synergism in combining two immunotherapy medications, Nivolumab and Ipilimumab. CHECKMATE 9LA combined immunotherapy with only two cycles of chemotherapy (Chemo-light), and CHECKMATE-227 showed synergism of combining Nivolumab and Ipilimumab (Chemo-Free). Clearly these protocols could be suitable to part of the patients with low PDL-1 expression levels. The caveat for combined immune blockage with Nivolumab and Ipilimumab is the increase in immune related adverse events.

5.6. Durvalumab after Chemoradiotherapy in Stage III NSCLC

The PACIFIC trial tested the effect of adjuvant Durvalumab after Chemoradiotherapy in Stage III NSCLC [121,122]. PFS and OS were longer among patients who received durvalumab than among those who received placebo in patients with tumor cells with PD-L1 expression of more than 1% [121,123–125]. Hypofractionated thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy is currently studied in the TRADE-hypo trial [126] and the SPIRAL-RT study [127].
5.7. Driver Mutations

Patients with NSCLC who have a driver mutation within the tumor cells, should be considered for treatment with targeted therapies. Review of targeted therapies is beyond the scope of this article. Examples of targeted therapies include Alectinib [128]/Brigatinib [17]/Ceritinib [129]/Crizotinib [130] for patients ALK/EML4 [14,16] fusion gene. Osimertinib [131]/Erlotinib [132]/Afatinib [133]/Gefitinib [132] for patients with EGFR mutation. Crizotinib [134]/Entrectinib [135] for patients with ROS1-translocated tumors; Dabrafenib with [136,137] or without [138] Trametinib, or Vemurafenib [139] for patients with BRAF V600E mutation; Capmatinib [140] for patients with MET exon 14 skipping; and Selpercatinib for patients with RET rearrangement [141].

6. Conclusions

Immunotherapy is an important treatment modality for NSCLC. Tailoring the treatment to each patient is a key for achieving best benefit. While the goal should be to utilize in the first line “chemotherapy free” or “minimal chemotherapy” protocols, it is important to know which patients do not benefit from these regimens. Protocols combining immunotherapy and chemotherapy are important in the first line, especially for nonsmokers.

Author Contributions: Conceptualization, N.J.N. and A.A.; writing—original draft preparation, N.J.N. and A.A.; writing—review and editing, N.J.N., M.G. and A.A. All authors have read and agreed to the published version of the manuscript

Funding: This research received no external funding.

Conflicts of Interest: N.J.N., M.G.: None. A.A. declares: Speaker fees and consulting: MSD, Roche, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Pfizer, BMS, Novartis, Merck Serono, Sanofi, Oncotest-Teva, Medison, AbbVie, Takeda. Grants: ALTMAN. Board membership: Israeli Lung Cancer Advocacy Group.

References
1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30. [CrossRef] [PubMed]
2. Zappa, C.; Mousa, S.A. Non-small cell lung cancer: Current treatment and future advances. Transl. Lung Cancer Res. 2016, 5, 288–300. [CrossRef] [PubMed]
3. Turnis, M.E.; Andrews, L.P.; Vignali, D.A.A. Inhibitory receptors as targets for cancer immunotherapy. Eur. J. Immunol. 2015, 45, 1892–1905. [CrossRef] [PubMed]
4. Wherry, E.J.; Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 2015, 15, 486–499. [CrossRef] [PubMed]
5. Francisco, L.M.; Sage, P.T.; Sharpe, A.H. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 2010, 236, 219–242. [CrossRef]
6. Paulsen, E.-E.; Kilvaer, T.K.; Khanehkenari, M.R.; Al-Saad, S.; Hald, S.M.; Andersen, S.; Richardsen, E.; Ness, N.; Busund, L.-T.; Brennes, R.M.; et al. Assessing PDL-1 and PD-1 in Non–Small Cell Lung Cancer: A Novel Immunoscore Approach. Clin. Lung Cancer 2017, 18, 220–233.e8. [CrossRef]
7. Poole, R.M. Pembrolizumab: First Global Approval. Drugs 2014, 74, 1973–1981. [CrossRef]
8. Brahmer, J.R.; Hammers, H.; Lipson, E.J. Nivolumab: Targeting PD-1 to bolster antitumor immunity. Future Oncol. 2015, 11, 1307–1326. [CrossRef]
9. Lee, H.T.; Lee, J.Y.; Lim, H.; Lee, S.H.; Moon, Y.J.; Pyo, H.J.; Ryu, S.E.; Shin, W.; Heo, Y-S. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci. Rep. 2017, 7, 5532. [CrossRef]
10. Buchbinder, E.L; Desai, A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am. J. Clin. Oncol. 2016, 39, 98–106. [CrossRef]
11. Genova, C.; Rijavec, E.; Barletta, G.; Sini, C.; Dal Bello, M.G.; Truini, M.; Murolo, C.; Pronzato, P.; Grossi, F. Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer. Expert Opin. Biol. Ther. 2012, 12, 939–948. [CrossRef] [PubMed]
12. Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Schadendorf, D.; Dummer, R.; Smylie, M.; Rutkowski, P.; et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N. Engl. J. Med.* 2015, 373, 23–34. [CrossRef] [PubMed]

13. Wei, S.C.; Anang, N.-A.A.S.; Sharma, R.; Andrews, M.C.; Reuben, A.; Levine, J.H.;Cogdill, A.P.; Mancuso, J.J.; Wargo, J.A.; Pe‘er, D.; et al. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. *Proc. Natl. Acad. Sci. USA* 2019, 116, 22699–22709. [CrossRef] [PubMed]

14. Soda, M.; Choi, Y.L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; et al. Identification of the transforming EML4-ALK mutation gene in non-small-cell lung cancer. *Nature* 2007, 448, 516–519. [CrossRef] [PubMed]

15. Zhou, W.; Ercan, D.; Chen, M.; Yun, C.-H.; Li, D.; Capelletti, M.; Cortot, A.B.; Chirieac, L.; Iacob, R.E.; Padera, R.; et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. *Nature* 2009, 462, 1070–1074. [CrossRef] [PubMed]

16. Choi, Y.L.; Soda, M.; Yamashita, Y.; Ueno, T.; Takashima, J.; Nakajima, T.; Yatabe, Y.; Takeuchi, K.; Hamada, T.; Haruta, H.; et al. EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors. *N. Engl. J. Med.* 2010, 363, 1734–1739. [CrossRef]

17. Camidge, D.R.; Kim, H.R.; Ahn, M.-J.; Yang, J.C.-H.; Han, J.-Y.; Lee, J.-S.; Hochmair, M.J.; Li, J.Y.C.; Chang, G.-C.; Lee, K.H.; et al. Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer. *N. Engl. J. Med.* 2018, 379, 74–87. [CrossRef]

18. Maemondo, M.; Inoue, A.; Kobayashi, K.; Sugawara, S.; Oizumi, S.; Isebe, H.; Gemma, A.; Harada, M.; Yoshizawa, H.; Kinoshita, I.; et al. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR. *N. Engl. J. Med.* 2010, 362, 2380–2388. [CrossRef] [PubMed]

19. Soria, J.-C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K.H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; et al. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. *N. Engl. J. Med.* 2017, 378, 113–125. [CrossRef]

20. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. *Nat. Rev. Cancer* 2012, 12, 252–264. [CrossRef]

21. Bristol Myers Squibb. OPDIVO™ (Nivolumab) [Package Insert]. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125554s083lbl.pdf (accessed on 9 May 2020).

22. Carbone, D.P.; Reck, M.; Paz-Ares, L.; Creehan, B.; Horn, L.; Steins, M.; Felip, E.; van den Heuvel, M.M.; Ciuleanu, T.E.; Badin, F.; et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* 2017, 376, 2415–2426. [CrossRef]

23. Kobayashi, T.; Iwama, S.; Yasuda, Y.; Okada, N.; Tsunekawa, T.; Onoue, T.; Takagi, H.; Hagiwara, D.; Ito, Y.; Morishita, Y. Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: A prospective study. *J. Endocr. Soc.* 2018, 2, 241–251. [CrossRef]

24. Yamauchi, I.; Sakane, Y.; Fukuda, Y.; Fujii, T.; Taura, D.; Hirata, M.; Hirota, K.; Ueda, Y.; Kanai, Y.; Yamashita, Y. Clinical features of nivolumab-induced thyroiditis: A case series study. *Thyroid* 2017, 27, 894–901. [CrossRef]

25. Jotatsu, T.; Oda, K.; Yamaguchi, Y.; Noguchi, S.; Kawanami, T.; Kido, T.; Satoh, M.; Yatera, K. Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab. *Immunotherapy* 2018, 10, 85–91. [CrossRef]

26. Dudzinska, M.; Szczysyrek, M.; Wojis-Krawczyk, K.; Swirska, J.; Chmielewska, I.; Zwolak, A. Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review. *Cancers* 2020, 12, 2314. [CrossRef]

27. Yoshino, K.; Nakayama, T.; Ito, A.; Sato, E.; Kitano, S. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: Potential role of Th1-dominant immune response in immune-related adverse events: Two case reports. *BMC Cancer* 2019, 19, 1019. [CrossRef]

28. Mathew Thomas, V.; Bindal, P.; Ann Alexander, S.; McDonald, K. Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor. *J. Oncol. Pharm. Pract.* 2020, 26, 459–461. [CrossRef]

29. Vandrimer, J.W.; Singer, Z.; Harshberger, C. Severe hyponatremia and immune nephritis following an initial infusion of nivolumab. *Target. Oncol.* 2016, 11, 533–536. [CrossRef]

30. Merck Sharp & Dohme Corp. KEYTRUDA®(Pembrolizumab) [Package Insert]. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s084lbl.pdf (accessed on 9 June 2020).
31. Mok, T.S.K.; Wu, Y.L.; Kudaba, I.; Kowalski, D.M.; Cho, B.C.; Turna, H.Z.; Castro, G., Jr.; Srinuninnimit, V.; Laktionov, K.K.; Bondarenko, I.; et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. *Lancet Lond. Engl.* 2019, 393, 1819–1830. [CrossRef]

32. Reck, M.; Rodriguez-Abrue, D.; Robinson, A.G.; Hui, R.; Csősz, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2019, 37, 537–546. [CrossRef]

33. Zhou, C.; Klionsky, Y.; Treasure, M.E.; Bruno, D.S. Pembrolizumab-induced immune-mediated colitis in a patient with concurrent Clostridium difficile infection. *Case Rep. Oncol.* 2019, 12, 164–170. [CrossRef]

34. Alavi, K.; Long, G.V.; Sinclair, E.C.; Kench, J.G.; McKenzie, C.A. Histopathology of pembrolizumab-induced hepatitis: A case report. *Pathology* 2017, 49, 789–792. [CrossRef]

35. Kobayashi, K.; Nakachi, I.; Mitsuishi, A.; Arai, D.; Sakurai, K.; Masaki, K.; Chiyotani, A.; Takahashi, H.; Tahara, T.; Soejima, K. Successful Retreatment Using Pembrolizumab for Non-Small-cell Lung Cancer After Severe Immune-Related Hepatitis: A Case Report. *Clin. Lung Cancer* 2020, 21, e30. [CrossRef]

36. Ahmed, M.; Francis, G. Pembrolizumab-Induced Microscopic Colitis. *Am. J. Gastroenterol.* 2018, 113, 629–630. [CrossRef]

37. Aivazian, K.; Long, G.V.; Sinclair, E.C.; Kench, J.G.; McKenzie, C.A. Histopathology of pembrolizumab-induced hepatitis: A case report. *Am. J. Kidney Dis.* 2020, 75, 372–375. [CrossRef]

38. Kobayashi, K.; Nakachi, I.; Mitsuishi, A.; Arai, D.; Sakurai, K.; Masaki, K.; Chiyotani, A.; Takahashi, H.; Tahara, T.; Soejima, K. Successful Retreatment Using Pembrolizumab for Non-Small-cell Lung Cancer After Severe Immune-Related Hepatitis: A Case Report. *Clin. Lung Cancer* 2020, 21, e30. [CrossRef]

39. Kawaji, L.D.R.; Villanueva, M.G.M.; Villa, M.L. SUN-276 Pembrolizumab-Induced Secondary Adrenal Insufficiency Presenting as Severe Hyponatremia in an 80-Year-Old Male. *J. Endocr. Soc.* 2020, 4, SUN-276. [CrossRef]

40. Oristrell, G.; Bañeras, J.; Ros, J.; Muñoz, E. Cardiac tamponade and adrenal insufficiency due to pembrolizumab: A case report. *Eur. Heart J. Case Rep.* 2018, 2, yty038. [CrossRef]

41. Imblum, B.A.; Baloch, Z.W.; Fraker, D.; LiVolsi, V.A. Pembrolizumab-induced thyroiditis. *Endocr. Pathol.* 2019, 30, 163–167. [CrossRef] [PubMed]

42. Matsuoka, N.; Tsuji, K.; Ichihara, E.; Hara, T.; Fukushima, K.; Toma, K.; Kitamura, S.; Inagaki, K.; Sugiyama, H.; Wada, J. Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: A case report. *BMC Nephrol.* 2020, 21, 1–5. [CrossRef]

43. Garon, E.B.; Moskovitz, B.; Hui, R.; Leiby, N.; Babanoukian, A.S.; Eder, J.P.; Patnaik, A.; Aggarwal, C.; Gubens, M.; Horn, L.; et al. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer. *N. Engl. J. Med.* 2015, 372, 2018–2028. [CrossRef]

44. Maamari, J.; Yeung, S.-C.J.; Chaftari, P.S. Diabetic ketoacidosis induced by a single dose of pembrolizumab. *Am. J. Emerg. Med.* 2019, 37, 376.e1–376.e2. [CrossRef] [PubMed]

45. Chae, Y.K.; Chiec, L.; Mohindra, N.; Gentzler, R.; Patel, J.; Giles, F. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. *Diabetes Med.* 2017, 66, 25–32. [CrossRef]

46. Shirali, A.C.; Perazella, M.A.; Gettinger, S. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. *Am. J. Kidney Dis.* 2016, 68, 287–291. [CrossRef]

47. Taki, T.; Oda, N.; Fujioka, Y.; Mitani, R.; Tokura, T.; Takata, I.; Oshiro, Y.; Takigawa, N. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab following Tubulointerstitial Nephritis due to Pembrolizumab. *Intern. Med.* 2020, 29, 1639–1642. [CrossRef]

48. Genentech Inc. TECENTRIQ® (Atezolizumab) [Package Insert]. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s028lbl.pdf (accessed on 9 June 2020).

49. Li, J.; Deng, X.; Wang, B.; Li, W. Fatal outcome of atezolizumab in a patient with immune-mediated pneumonitis, thrombocytopenia, and cardiac dysfunction: A case report. *Int. J. Clin. Pharmacol. Ther.* 2019, 57, 607–611. [CrossRef]

50. Hsu, P.-C.; Li, S.-H.; Yang, C.-T. Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis. *J. Thorac. Oncol.* 2018, 13, e227–e230. [CrossRef]
51. Ikeda, S.; Kato, T.; Kenmotsu, H.; Ogura, T.; Iwasawa, S.; Sato, Y.; Harada, T.; Kubota, K.; Tokito, T.; Okamoto, I. A Phase II study of atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonias. J. Thorac. Oncol. 2020. [CrossRef]

52. Fehrenbacher, L.; Spira, A.; Ballinger, M.; Kowanetz, M.; Vansteenkiste, J.; Mazieres, J.; Park, K.; Smith, D.; Artal-Cortes, A.; Lewanski, C.; et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016, 387, 1837–1846. [CrossRef]

53. Schmid, P.; Rugo, H.S.; Adams, S.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Diéras, V.; Henschel, V.; Molinero, L.; Chui, S.Y.; et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020, 21, 44–59. [CrossRef]

54. Kanie, K.; Iguchi, G.; Bando, H.; Fujita, Y.; Odake, Y.; Yoshida, K.; Matsumoto, R.; Fukuoka, H.; Ogawa, W.; Takahashi, Y. Two cases of atezolizumab-induced hypophysitis. J. Endocr. Soc. 2018, 2, 91–95. [CrossRef]

55. Socinski, M.A.; Jotte, R.M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodríguez-Aguayo, D.; Moro-Sibilot, D.; Thomas, C.A.; Barlesi, F.; et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. New Engl. J. Med. 2018, 378, 2288–2301. [CrossRef] [PubMed]

56. West, H.; McCleod, M.; Hussein, M.; Morabito, A.; Rittmeyer, A.; Conter, H.J.; Kopp, H.-G.; Daniel, D.; Thajudeen, B.; Madhrira, M.; Bracamonte, E.; Cranmer, L.D. Ipilimumab granulomatous interstitial nephritis. [CrossRef]

57. Gaballa, S.; Hlaing, K.M.; Mahler, N.; Moursy, S.; Ahmed, A. A Rare Case of Immune-Mediated Primary Adrenal Insufficiency With Cytotoxic T-Lymphocyte Antigen-4 Inhibitor Ipilimumab in Metastatic Melanoma of Lung and Neck of Unknown Primary. Cureus 2020, 12, e8602. [CrossRef] [PubMed]

58. Schmit, P.; Rugo, H.S.; Adams, S.; Rodriguez-Aguayo, D.; Moro-Sibilot, D.; Thomas, C.A.; Barlesi, F.; et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020, 21, 44–59. [CrossRef]

59. Kanie, K.; Iguchi, G.; Bando, H.; Fujita, Y.; Odake, Y.; Yoshida, K.; Matsumoto, R.; Fukuoka, H.; Ogawa, W.; Takahashi, Y. Two cases of atezolizumab-induced hypophysitis. J. Endocr. Soc. 2018, 2, 91–95. [CrossRef]

60. West, H.; McCleod, M.; Hussein, M.; Morabito, A.; Rittmeyer, A.; Conter, H.J.; Kopp, H.-G.; Daniel, D.; Thajudeen, B.; Madhrira, M.; Bracamonte, E.; Cranmer, L.D. Ipilimumab granulomatous interstitial nephritis. [CrossRef]

61. Socinski, M.A.; Jotte, R.M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodríguez-Aguayo, D.; Moro-Sibilot, D.; Thomas, C.A.; Barlesi, F.; et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. New Engl. J. Med. 2018, 378, 2288–2301. [CrossRef] [PubMed]

62. West, H.; McCleod, M.; Hussein, M.; Morabito, A.; Rittmeyer, A.; Conter, H.J.; Kopp, H.-G.; Daniel, D.; Thajudeen, B.; Madhrira, M.; Bracamonte, E.; Cranmer, L.D. Ipilimumab granulomatous interstitial nephritis. [CrossRef]
71. Garassino, M.C.; Cho, B.-C.; Kim, J.-H.; Mazières, J.; Vansteenkiste, J.; Lena, H.; Corral Jaime, J.; Gray, J.E.; Powderly, J.; Chouaid, C.; et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): An open-label, single-arm, phase 2 study. *Lancet Oncol.* 2018, 19, 521–536. [CrossRef]

72. Tonk, E.H.J.; van Lindert, A.S.R.; Verhoeff, J.J.C.; Suijkerbuijk, K.P.M. Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab. *Case Rep. Oncol.* 2019, 12, 621–624. [CrossRef] [PubMed]

73. Nakamura, M.; Otsuka, T.; Hayashi, R.; Horita, T.; Ota, M.; Sakurai, N.; Takano, H.; Hayashi, T.; Kumagai, M.; Yamada, S. Durvalumab-Induced Immune-Related Hepatitis in a Patient with Non-small Cell Lung Cancer. *Intern. Med.* 2020, 59, 2711–2717. [CrossRef]

74. Yang, H.; Shen, K.; Zhu, C.; Li, Q.; Zhao, Y.; Ma, X. Safety and efficacy of durvalumab (MEDI4736) in various solid tumors. *Drug Des. Dev. Ther.* 2018, 12, 2085. [CrossRef] [PubMed]

75. Coleman, E.; Ko, C.; Dai, F.; Tomayko, M.M.; Kluger, H.; Leventhal, J.S. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. *J. Am. Acad. Dermatol.* 2019, 80, 990–997. [CrossRef]

76. Lin, W.-H.; Lee, K.-Y.; Lee, W.-R.; Shih, Y.-H. Durvalumab-induced de novo annular psoriasiform drug eruption successfully treated with a combination of narrowband ultraviolet B phototherapy and topical treatment. *J. Dermatol.* 2020, 47, 1041–1045. [CrossRef] [PubMed]

77. Gorantla, Y.; Amblee, A.; Lee, Y.L.; Yap, S.E.T. SAT-506 Rare Case of Durvalumab-Induced Thyroiditis, Transient Secondary Adrenal Insufficiency and Autoimmune Diabetes. *J. Endocr. Soc.* 2020, 4, SAT-506. [CrossRef]

78. Mengibar, J.L.; Capel, I.; Bonfill, T.; Mazarico, I.; Espuña, L.C.; Caixàs, A.; Rigla, M. Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment. *Endocrinol. Diabetes Metab. Case Rep.* 2019. [CrossRef]

79. Patel, S.; Chin, V.; Greenfield, J.R. Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism. *Endocrinol. Diabetes Metab. Case Rep.* 2019, 2019, 98. [CrossRef]

80. Schiller, J.H.; Harrington, D.; Belani, C.P.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D.H. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer. *N. Engl. J. Med.* 2002, 346, 92–98. [CrossRef]

81. Scagliotti, G.V.; Parikh, P.; von Pawel, J.; Manegold, C.; Serwatowski, P.; Gatzemeier, U.; Digumarti, R.; Zukin, M.; et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2008, 26, 3543–3551. [CrossRef]

82. Ozkok, A.; Edelstein, C.L. Pathophysiology of cisplatin-induced acute kidney injury. *Biomed. Res. Int.* 2014, 967826. [CrossRef]

83. Rowinsky, E.K.; Donehower, R.C. Paclitaxel (Taxol). *N. Engl. J. Med.* 1995, 332, 1004–1014. [CrossRef]

84. Verweij, J.; Clavel, M.; Chevalier, B. Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind. *Ann. Oncol. Off. J. Eur. Soc. Med Oncol.* 1994, 5, 495–505. [CrossRef]

85. Vu, T.; Ellard, S.; Speers, C.H.; Taylor, S.C.M.; de Lemos, M.L.; Hu, F.; Kuik, K.; Olivotto, I.A. Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: A population-based evaluation. *Ann. Oncol.* 2008, 19, 461–464. [CrossRef]

86. Jones, S.E.; Erban, J.; Overmoyer, B.; Budd, G.T.; Hutchins, L.; Lower, E.; Laufman, L.; Sundaram, S.; Urba, W.J.; Pritchard, K.I.; et al. Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer. *J. Clin. Oncol.* 2005, 23, 5542–5551. [CrossRef]

87. Scotté, F.; Tourani, J.-M.; Banu, E.; Peyrommaure, M.; Levy, E.; Marsan, S.; Magherini, E.; Fabre-Guillèvin, E.; Andrieu, J.-M.; Oudard, S. Multicenter Study of a Frozen Glove to Prevent Docetaxel-Induced Onychoysis and Cutaneous Toxicity of the Hand. *J. Clin. Oncol.* 2005, 23, 4424–4429. [CrossRef] [PubMed]

88. Martin, M.; Segui, M.A.; Antón, A.; Ruiz, A.; Ramos, M.; Adrover, E.; Aranda, I.; Rodríguez-Lescure, A.; Große, R.; Calvo, L.; et al. Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. *N. Engl. J. Med.* 2010, 363, 2200–2210. [CrossRef]

89. Lee, H.; Park, S.; Kang, J.E.; Lee, H.M.; Kim, S.A.; Rhie, S.J. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis. *Sci. Rep.* 2020, 10, 530. [CrossRef]
90. Schmid, P.; Adams, S.; Rugo, H.S.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Diéras, V.; Hegg, R.; Im, S.-A.; Shaw Wright, G.; et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. *N. Engl. J. Med.* 2018, 379, 2108–2121. [CrossRef] [PubMed]

91. Eli, L. GEMZAR (Gemcitabine) [Package Insert]. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021462s053lbl.pdf (accessed on 9 October 2020).

92. Conroy, T.; Desesquiere, F.; Ychou, M.; Bouché, O.; Guimbaud, R.; Béouin, Y.; Adenis, A.; Raoul, J.-L.; Gourgou-Bourgade, S.; de la Foucheardière, C.; et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. *N. Engl. J. Med.* 2011, 364, 1817–1825. [CrossRef]

93. Sabria-Trias, J.; Bonnau, F.; Sioniac, M. Severe interstitial pneumonitis related to gemcitabine. *Rev. Des Mal. Respir.* 2002, 19, 645–647.

94. Pavlakis, N.; Bell, D.R.; Millward, M.J.; Levi, J.A. Fatal pulmonary toxicity resulting from treatment with gemcitabine. *Cancer Interdiscip. Int. J. Am. Cancer Soc.* 1997, 80, 286–291. [CrossRef]

95. De Pas, T.; Curigliano, G.; Franceschelli, L.; Catania, C.; Spaggiari, L.; De Braud, F. Gemcitabine-induced systemic capillary leak syndrome. *Ann. Oncol.* 2001, 12, 1651–1652. [CrossRef]

96. Pulkkanen, K.; Kataja, V.; Johansson, R. Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: A case report. *J. Chemother.* 2003, 15, 287–289. [CrossRef]

97. Els, N.J.V.; Miller, V. Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. *Chest* 1998, 114, 1779–1781.

98. Russell, M.T.; Nassif, A.S.; Cacayorin, E.D.; Awwad, E.; Perman, W.; Dunphy, E. Gemcitabine-associated posterior reversible encephalopathy syndrome. *Magn. Reson. Imaging* 2001, 19, 129–132. [CrossRef]

99. Kwon, E.J.; Kim, S.W.; Kim, K.K.; Seo, H.S.; Kim, D.Y. A case of gemcitabine and cisplatin associated posterior reversible encephalopathy syndrome. *Cancer Res. Treat. Off. J. Korean Cancer Assoc.* 2009, 41, 53. [CrossRef]

100. Lilly USA LLC. ALIMTA (Pemetrexed) [Package Insert]. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021462s053lbl.pdf (accessed on 13 September 2020).

101. Huang, J.-J.; Ma, S.-X.; Hou, X.; Wang, Z.; Zeng, Y.-D.; Qin, T.; Dinglin, X.-X.; Chen, L.-K. Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer. *Chin. J. Cancer* 2015, 34, 94–98. [CrossRef] [PubMed]

102. Scheinpflug, K.; Menzel, C.; Koch, A.; Kähl, C.; Achenbach, H.J. Toxic epidermal necrolysis related to cisplatin and pemetrexed for metastatic non-small cell lung cancer. *OncoI. Res. Treat.* 2012, 35, 600–603. [CrossRef]

103. Paz-Ares, L.; Luft, A.; Vicente, D.; Tafreshi, A.; Gümuş, M.; Mazières, J.; Hermès, B.; Çay Şenler, F.; Csósz, T.; Fülöp, A.; et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* 2018, 379, 2040–2051. [CrossRef]

104. Gadgeel, S.; Rodriguez-Arroyo, D.; Speranza, G.; Esteban, E.; Felip, E.; Döméne, M.; Hui, R.; Hochmair, M.J.; Clingan, P.; Powell, S.F.; et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Non-Squamous Non-Small-Cell Lung Cancer. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2020, 38, 1505–1517. [CrossRef]

105. Gandhi, L.; Rodríguez-Abreu, D.; Porta, V.; Guimbaud, R.; Béouin, Y.; Adenis, A.; Raoul, J.-L.; Gourgou-Bourgade, S.; de la Foucheardière, C.; et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer with High PD-L1 Expression. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-first-line-treatment-metastatic-nscle-high-pd-l1-expression (accessed on 31 May 2020).

106. Herbst, R.S.; Giaccone, G.; de Marinis, F.; Reinmuth, N.; Vergnenegre, A.; Barrios, C.H.; Morise, M.; Felip, E.; Andric, Z.; Geater, S.; et al. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC. *N. Engl. J. Med.* 2020, 383, 1328–1339. [CrossRef]
109. Reck, M.; Mok, T.S.K.; Nishio, M.; Jotte, R.M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodríguez-Abreu, D.; Moro-Sibilot, D.; et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. *Lancet. Respir. Med.* 2019, 7, 387–401. [CrossRef]

110. Reck, M.; Weehler, T.; Orlandi, F.; Nogami, N.; Barone, C.; Moro-Sibilot, D.; Shtivelband, M.; González Larriba, J.L.; Rothenstein, J.; Früh, M.; et al. Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2020. [CrossRef]

111. Hellmann, M.D.; Paz-Ares, L.; Bernabe Caro, R.; Zurawski, B.; Kim, S.-W.; Carcereny Costa, E.; Park, K.; Alexandru, A.; Lupinacci, L.; de la Mora Jimenez, E.; et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* 2019, 381, 2020–2031. [CrossRef]

112. Wolchok, J.D.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Wagstaff, J.; Schadendorf, D.; Ferrucci, P.F.; et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *N. Engl. J. Med.* 2017, 377, 1345–1356. [CrossRef] [PubMed]

113. Reck, M.; Ciuleanu, T.-E.; Dols, M.C.; Schenker, M.; Zurawski, B.; Menezes, J.; Richardet, E.; Bennouna, J.; Felip, E.; Juan-Vidal, O. Nivolumab (NIVO) + Ipilimumab (IPI)+ 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs 4 Cycles Chemo as First-Line (1L) Treatment for Stage IV/Recurrent Non-Small-Cell Lung Cancer (NSCLC): CheckMate 9LA; American Society of Clinical Oncology: Alexandria, VA, USA, 2020.

114. Howlader, N.; Forjaz, G.; Mooradian, M.J.; Meza, R.; Kong, C.Y.; Cronin, K.A.; Mariotto, A.B.; Lowy, D.R.; Feuer, E.J. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. *N. Engl. J. Med.* 2020, 383, 640–649. [CrossRef]

115. Reck, M.; Kerr, K.M.; Grohé, C.; Manegold, C.; Pavlakis, N.; Paz-Ares, L.; Huber, R.M.; Popat, S.; Thatcher, N.; Park, K.; et al. Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: A separate disease entity? *Future Oncol. Lond. Engl.* 2019, 15, 1363–1383. [CrossRef] [PubMed]

116. Seliger, B. Basis of PD1/PD-L1 Therapies. *J. Clin. Med.* 2019, 8, 2168. [CrossRef]

117. Álvarez-Argote, J.; Dasanu, C.A. Durvalumab in cancer medicine: A comprehensive review. *Expert Opin. Biol. Ther.* 2019, 19, 927–935. [CrossRef]

118. Picardo, S.L.; Doi, J.; Hansen, A.R. Structure and Optimization of Checkpoint Inhibitors. *Cancers* 2020, 12, 38. [CrossRef]

119. Antonia, S.; Goldberg, S.B.; Balmanoukian, A.; Chait, J.E.; Sanborn, R.E.; Gupta, A.; Narwal, R.; Steele, K.; Gu, Y.; Karakunnel, J.J.; et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: A multicentre, phase 1b study. *Lancet. Oncol.* 2016, 17, 299–308. [CrossRef]

120. Rizvi, N.A.; Cho, B.C.; Reinmuth, N.; Lee, K.H.; Luft, A.; Ahn, M.J.; van den Heuvel, M.M.; Cobo, M.; Vicente, D.; Smolin, A.; et al. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial. *JAMA Oncol.* 2020, 6, 661–674. [CrossRef]

121. Antonia, S.J.; Villegas, A.; Daniel, D.; Vicente, D.; Murakami, S.; Hui, R.; Kurata, T.; Chiappori, A.; Lee, K.H.; de Wit, M.; et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. *N. Engl. J. Med.* 2018, 379, 2342–2350. [CrossRef]

122. Gray, J.E.; Villegas, A.; Daniel, D.; Vicente, D.; Murakami, S.; Hui, R.; Kurata, T.; Chiappori, A.; Lee, K.H.; Cho, B.C.; et al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. *J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer* 2020, 15, 288–293. [CrossRef]

123. Antonia, S.J. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply. *N. Engl. J. Med.* 2019, 380, 990. [CrossRef]

124. Zhang, T.; Wu, Y.; Zheng, S.; Cheng, G.; He, X.; Bi, N. Durvalumab after concurrent chemoradiotherapy in a patient with chemotherapy-resistant unresectable stage III non-small cell lung cancer: A case report. *Ann. Palliat. Med.* 2020, 9, 2375–2380. [CrossRef]

125. Jung, H.A.; Noh, J.M.; Sun, J.M.; Lee, S.H.; Ahn, J.S.; Ahn, M.J.; Pyo, H.; Ahn, Y.C.; Park, K. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. *Lung Cancer Amst. Neth.* 2020, 146, 23–29. [CrossRef] [PubMed]
126. Bozorgmehr, F.; Chung, I.; Christopoulos, P.; Krisam, J.; Schneider, M.A.; Brückner, L.; Mueller, D.W.; Thomas, M.; Rieken, S. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy—Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: Study protocol of the TRADE-hypo trial. *BMC Cancer* 2020, 20, 806. [CrossRef]

127. Yamada, T.; Uchino, J.; Chihara, Y.; Shimamoto, T.; Iwasaku, M.; Tamiya, N.; Kaneko, Y.; Kiyomi, F.; Takayama, K. Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study). *Ther. Adv. Med Oncol.* 2020, 12, 7841. [CrossRef]

128. Peters, S.; Camidge, D.R.; Shaw, A.T.; Gadgeel, S.; Ahn, J.S.; Kim, D.-W.; Ou, S.-H.I.; Pérol, M.; Dziadzio, R.; Rosell, R.; et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer. *N. Engl. J. Med.* 2017, 377, 829–838. [CrossRef]

129. Shaw, A.T.; Kim, D.-W.; Mehra, R.; Tan, D.S.W.; Felip, E.; Chow, L.Q.M.; Camidge, D.R.; Vansteenkiste, J.; Sharma, S.; De Pas, T.; et al. Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer. *N. Engl. J. Med.* 2014, 370, 1189–1197. [CrossRef]

130. Solomon, B.J.; Mok, T.; Kim, D.-W.; Wu, Y.-L.; Nakagawa, K.; Mekhail, T.; Felip, E.; Cappuzzo, F.; Paolini, J.; Usari, T.; et al. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. *N. Engl. J. Med.* 2014, 371, 2167–2177. [CrossRef] [PubMed]

131. Cataldo, V.D.; Gibbons, D.L.; Pérez-Soler, R.; Quintás-Cardama, A. Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib. *N. Engl. J. Med.* 2011, 364, 947–955. [CrossRef]

132. Sequist, L.V.; Yang, J.C.-H.; Yamamoto, N.; O’Byrne, K.; Hirsh, V.; Mok, T.; Geater, S.L.; Orlov, S.; Tsai, C.-M.; Boyer, M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *J. Clin. Oncol.* 2013, 31, 3327–3334. [CrossRef]

133. Al-Salama, Z.T.; Keam, S.J. Entrectinib: First Global Approval. *Drugs* 2019, 79, 1477–1483. [CrossRef]

134. Planchard, D.; Smit, E.F.; Groen, H.J.M.; Mazieres, J.; Besse, B.; Helland, Å.; Giannone, V.; D’Amelio, A.M., Jr.; Zhang, P.; Mookerjee, B.; et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial. *Lancet. Oncol.* 2017, 18, 1307–1316. [CrossRef]

135. Planchard, D.; Besse, B.; Groen, H.J.M.; Souquet, P.J.; Quoix, E.; Baik, C.S.; Barlesi, F.; Kim, T.M.; Mazieres, J.; Novello, S.; et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: An open-label, multicentre phase 2 trial. *Lancet. Oncol.* 2016, 17, 984–993. [CrossRef]

136. Planchard, D.; Kim, T.M.; Mazieres, J.; Quoix, E.; Riely, G.; Barlesi, F.; Souquet, P.J.; Smit, E.F.; Groen, H.J.; Kelly, R.J.; et al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: A single-arm, multicentre, open-label, phase 2 trial. *Lancet. Oncol.* 2016, 17, 642–650. [CrossRef]

137. Mazières, J.; Croiset, C.; Montané, L.; Barlesi, F.; Souquet, P.J.; Quantin, X.; Dubos-Arvis, C.; Otto, J.; Favier, L.; Avrillon, V.; et al. Vemurafenib in non-small-cell lung cancer patients with BRAF(V600) and BRAF(nonV600) mutations. *Ann. Oncol. Off. J. Eur. Soc. Med Oncol.* 2020, 31, 289–294. [CrossRef]

138. Wolf, J.; Seto, T.; Han, J.-Y.; Reguart, N.; Garon, E.B.; Groen, H.J.; Tan, D.S.-W.; Hida, T.; De Jonge, M.J.; Orlov, S.V. Capmatinib (INC280) in MET∆ex14-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC): Efficacy Data From the Phase II GEOMETRY Mono-1 Study; American Society of Clinical Oncology: Alexandria, VA, USA, 2019.
141. Subbiah, V.; Yang, D.; Velcheti, V.; Drilon, A.; Meric-Bernstam, F. State-of-the-Art Strategies for Targeting RET-Dependent Cancers. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2020, 38, 1209–1221. [CrossRef]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. 

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).